Telix Pharmaceuticals Stock

Telix Pharmaceuticals EBIT

Delisted·Jun 19, 2026

The EBIT of Telix Pharmaceuticals (TLX.AX) as of Aug 21, 2026 is 30.91 M USD. In the previous year, EBIT was 54.58 M USD — a change of -43.38% (lower).

EBIT

30.91 MUSD

YoY

-43.38%

Last updated:

In 2026, Telix Pharmaceuticals's EBIT was 30.91 M USD, a -43.38% increase from the 54.58 M USD EBIT recorded in the previous year.

The Telix Pharmaceuticals EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2024
54.58 base
Jan 1, 2025
30.91 base
Jan 1, 2026 (e)
-286.54 base
Jan 1, 2027 (e)
-331.55 base
Jan 1, 2028 (e)
-387.67 base
Jan 1, 2029 (e)
-420.15 base
Jan 1, 2030 (e)
-483.95 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (M USD)
2031 est -
2030 est -483.95
2029 est -420.15
2028 est -387.67
2027 est -331.55
2026 est -286.54
2025 30.91
2024 54.58
2023 12.29
2022 -58.89
2021 -76.95
2020 -35.60
2019 -28.36
2018 -17.51
2017 -6.16
Access this data via the Eulerpool API

Telix Pharmaceuticals Revenue

Telix Pharmaceuticals Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
516.55 M USD
54.58 M USD
33.69 M USD
Jan 1, 2025
803.79 M USD
30.91 M USD
-7.13 M USD
Jan 1, 2026 (e)
984.98 M USD
-286.54 M USD
12.84 M USD
Jan 1, 2027 (e)
1.14 B USD
-331.55 M USD
30.43 M USD
Jan 1, 2028 (e)
1.33 B USD
-387.67 M USD
87.24 M USD
Jan 1, 2029 (e)
1.44 B USD
-420.15 M USD
169.38 M USD
Jan 1, 2030 (e)
1.66 B USD
-483.95 M USD
267.86 M USD
Jan 1, 2031 (e)
2.15 B USD
0.00 USD
263.49 M USD

Telix Pharmaceuticals Margins

Telix Pharmaceuticals stock margins

The Telix Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Telix Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Telix Pharmaceuticals.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
61.85 %
10.57 %
6.52 %
Jan 1, 2025
47.51 %
3.84 %
-0.89 %
Jan 1, 2026 (e)
47.51 %
-29.09 %
1.30 %
Jan 1, 2027 (e)
47.51 %
-29.09 %
2.67 %
Jan 1, 2028 (e)
47.51 %
-29.09 %
6.55 %
Jan 1, 2029 (e)
47.51 %
-29.09 %
11.73 %
Jan 1, 2030 (e)
47.51 %
-29.09 %
16.10 %
Jan 1, 2031 (e)
47.51 %
0.00 %
12.25 %

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Telix Pharmaceuticals's EBIT

Telix Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Telix Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Telix Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Telix Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Telix Pharmaceuticals stock

EBIT of Telix Pharmaceuticals is 30.91 M USD in 2026.

EBIT of Telix Pharmaceuticals changed from 54.58 M USD to 30.91 M USD, representing a -43.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Telix Pharmaceuticals historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals